Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sequential AG and mFOLFIRINOX in Metastatic Pancreatic Adenocarcinoma
NCT03633734Phase 2Unknown
- Sponsor
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Start
- Jul 2018
- Primary completion
- Aug 2023
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of paclitaxel, gemcitabine, fluorouracil, irinotecan and oxaliplatin in pancreatic adenocarcinoma (PDAC), sponsored by Second Affiliated Hospital of Zhejiang University School of Medicine. Primary endpoint: Progression-free survival up to 60 months. Status: unknown.
02
Drugs
paclitaxelgemcitabinefluorouracilirinotecanoxaliplatin
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT03633734.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03633734.